EMERGENT BIOSOLUTIONS INC (EBS)       11.77  +0.16 (+1.38%)

11.77  +0.16 (+1.38%)

US29089Q1058 - Common Stock - Premarket: 12.35 +0.58 (+4.93%)

EMERGENT BIOSOLUTIONS INC11.77

NYSE:EBS (11/29/2022, 7:04:00 PM)+0.16 (+1.38%)

Premarket: 12.35 +0.58 (+4.93%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-08 2022-11-08/amc Earnings (Next) 01-09 2023-01-09
Ins Owners 4% Inst Owners 81.92%
Market Cap 587.18M Shares 49.89M
PE 4.62 Fwd PE 6.27
Dividend Yield N/A Analysts 74.55
IPO 11-15 2006-11-15

Stock Screener Links

Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

EBS Daily chart

Company Profile

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 2,416 full-time employees. The company went IPO on 2006-11-15. The firm is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. The company provides solutions for PHTs through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. The company offers TEMBEXA (brincidofovir) an antiviral for the treatment of smallpox in all age groups, including adults, and for patients who have difficulty swallowing.

Company Info

EMERGENT BIOSOLUTIONS INC

400 Professional Dr, Suite 400

Gaithersburg MARYLAND 20879

P: 12406313200.0

CEO: Robert G. Kramer

Employees: 2416

Website: https://emergentbiosolutions.com/

EBS News

News Image16 days ago - Emergent BioSolutionsEmergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach

Emergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studies...

News Image16 days ago - Emergent BioSolutionsEmergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach

Emergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studies

News Image21 days ago - Market News VideoEmergent BioSolutions is Now Oversold (EBS)News Image21 days ago - Investor's Business DailyWhy Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing

Biotech stocks were hammered Wednesday, including several that had good news.

News Image21 days ago - The Motley FoolEmergent BioSolutions (EBS) Q3 2022 Earnings Call Transcript

EBS earnings call for the period ending September 30, 2022.

News Image22 days ago - Emergent BioSolutionsEmergent BioSolutions Reports Financial Results For Third Quarter 2022

EBS Twits

Here you can normally see the latest stock twits on EBS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example